Neogen Corporation has appointed Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025. Riggsbee will report directly to CEO Mike Nassif and will lead the company’s global finance organization, overseeing financial planning, reporting, and capital allocation as Neogen pursues a strategic transformation focused on right‑sizing the cost base and deleveraging the balance sheet.
Riggsbee brings a decade of experience in corporate finance, having held senior finance roles at bioMérieux, Myriad Genetics, LabCorp, GE, and KPMG. His background in cost management and capital structure optimization aligns with Neogen’s recent actions, including the divestiture of its Cleaners & Disinfectants business and a $100 million debt repayment in Q1 FY2026. Neogen’s financial performance has been mixed in recent quarters: Q4 FY2025 revenue fell 4.8% year‑over‑year to $225.5 million with a net loss of $612.2 million largely due to a goodwill impairment; Q3 FY2025 revenue was $221.0 million with a net loss of $11.0 million; and Q1 FY2026 revenue was $209.2 million with a net income of $36.3 million.
David Naemura, the outgoing CFO, will remain in his role through the end of 2025 to ensure a smooth transition. Riggsbee’s compensation package includes a $600,000 base salary, a target annual bonus of 80% of salary, and an annual long‑term equity grant targeting $2,000,000. The appointment comes shortly after Mike Nassif’s elevation to CEO and President on August 11, 2025, marking a period of strategic realignment for the company.
Neogen’s leadership team expects Riggsbee to strengthen financial discipline, support growth initiatives, and navigate the company’s ongoing restructuring efforts, positioning Neogen to improve profitability and shareholder value in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.